ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Rosetta Genomics's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2017 was -336.40%.
As of today (2026-06-26), Rosetta Genomics's WACC % is 0.00%. Rosetta Genomics's ROIC % is 0.00% (calculated using TTM income statement data).
Rosetta Genomics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Rosetta Genomics (OTCPK:ROSGQ) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Rosetta Genomics's WACC % is 0.00%. Rosetta Genomics's ROIC % is 0.00% (calculated using TTM income statement data).
Rosetta Genomics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Rosetta Genomics ROIC % Related Terms
Rosetta Genomics ROIC % Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rosetta Genomics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics ROIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's ROIC % distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's ROIC % falls into.
Note:
The Operating Income data used here is two times the semi-annual (Jun. 2017) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (ROSGQ) has a ROIC % of -336.40% as of Jun. 2017. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' ROIC % too high?
Rosetta Genomics' current ROIC % is -336.40%.
How does Rosetta Genomics' ROIC % compare to TEAR and IDTA?
Rosetta Genomics' ROIC % of -336.40% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Diagnostics & Research company?
A good ROIC % depends on the Medical Diagnostics & Research industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current ROIC % is -336.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current ROIC % of -336.40%. The current ROIC % is -336.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current ROIC % is -336.40% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 